The oncology sector is a dynamic field that continues to push the boundaries of cancer research and treatment. Despite recent market corrections, the pursuit of innovative therapies to address the significant disease burden remains important. To gain deeper insights into the forces shaping this field, we interviewed several of our
Since the 1990s, we’ve seen an expansion in the gene therapy landscape, which is expected to continue growing in the coming years. (Cell Stem Cell) The global gene therapy market was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030, growing at a CAGR
Approximately 25% of individuals aged 25 and above may face a stroke during their lifetime. (WSO) Strokes can result from a blocked artery, also known as Acute Ischemic Stroke (AIS), causing severe brain damage, disability, or death. (CDC). Since 1987, only one FDA-approved drug, a thrombolytic agent, has been used
In recent years, businesses in industries like life sciences and biotech have embraced digital communication. This has led to hybrid work environments, virtual conferences, and the recognition of social media as a valuable tool. Scientists and investors more actively participate in social media platforms, especially LinkedIn, making it crucial for
2023 was a challenging year for the biotech industry. We collaborated with a diverse set of clients, each at varying stages of their fundraising endeavors. As we reflect on the past year, we’d like to take a moment to highlight the impressive milestones our clients have reached. Lexeo Therapeutics Lexeo
If you are developing an innovative treatment or cutting-edge therapeutics platform, you are familiar with the challenge of raising funds. Biotech and life science companies offer higher ROIs, but also higher investment risks, especially in the early stages. Hence, the challenge – how do you convince investors that your approach
What makes science both captivating and complicated is its intricacies. This can pose a challenge when it comes to communicating with investors because a minor detail can have a major impact. Most of our clients have a differentiated or novel mechanism of action (MOA), but the challenge is how to
Fundraising never stops in biotech, which is why company leaders need to continually refine their fundraising strategies. In this article, we are highlighting the top 3 mistakes we see biotech companies make when pitching to investors. These three key mistakes came up during a recent appearance by our CEO and
Theoria Creative is a marketing firm, enabling life sciences companies to clearly communicate complex science to investors, partners, and peers. We develop communication strategy, messaging, positioning, and prepare a set of illustrated materials that help companies clearly and succinctly articulate their value at high stakes meetings.
We share useful tips and company news in a monthly newsletter.
